PET-based treatment response evaluation in rectal cancer: prediction and validation

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):871-6. doi: 10.1016/j.ijrobp.2010.11.038. Epub 2011 Mar 5.

Abstract

Purpose: To develop a positron emission tomography (PET)-based response prediction model to differentiate pathological responders from nonresponders. The predictive strength of the model was validated in a second patient group, treated and imaged identical to the patients on which the predictive model was based.

Methods and materials: Fifty-one rectal cancer patients were prospectively included in this study. All patients underwent fluorodeoxyglucose (FDG) PET-computed tomography (CT) imaging both before the start of chemoradiotherapy (CRT) and after 2 weeks of treatment. Preoperative treatment with CRT was followed by a total mesorectal excision. From the resected specimen, the tumor regression grade (TRG) was scored according to the Mandard criteria. From one patient group (n = 30), the metabolic treatment response was correlated with the pathological treatment response, resulting in a receiver operating characteristic (ROC) curve based cutoff value for the reduction of maximum standardized uptake value (SUV(max)) within the tumor to differentiate pathological responders (TRG 1-2) from nonresponders (TRG 3-5). The applicability of the selected cutoff value for new patients was validated in a second patient group (n = 21).

Results: When correlating the metabolic and pathological treatment response for the first patient group using ROC curve analysis (area under the curve = 0.98), a cutoff value of 48% SUV(max) reduction was selected to differentiate pathological responders from nonresponders (specificity of 100%, sensitivity of 64%). Applying this cutoff value to the second patient group resulted in a specificity and sensitivity of, respectively, 93% and 83%, with only one of the pathological nonresponders being false positively predicted as pathological responding.

Conclusions: For rectal cancer, an accurate PET-based prediction of the pathological treatment response is feasible already after 2 weeks of CRT. The presented predictive model could be used to select patients to be considered for less invasive surgical interventions or even a "wait and see" policy. Also, based on the predicted response, early modifications of the treatment protocol are possible, which might result in an improved clinical outcome.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Chemoradiotherapy / methods*
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • Humans
  • Multimodal Imaging
  • Neoplasm Staging
  • Positron-Emission Tomography / methods*
  • Prospective Studies
  • ROC Curve
  • Radiopharmaceuticals / pharmacokinetics
  • Rectal Neoplasms / diagnostic imaging*
  • Rectal Neoplasms / metabolism
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / therapy*
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed
  • Tumor Burden

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18